| • |
For the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation |
| • |
For the treatment of adult patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate |
| • |
In combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: |
| |
| ◦ |
locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or |
| ◦ |
metastatic |
|
| • |
As a single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD‑L1 expression [Tumor Proportion Score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: |
| |
| ◦ |
locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or |
| ◦ |
metastatic |
|